USAntibiotics, the sole licensed American maker of penicillin-based Amoxicillin and Amoxil Clavulanate, the popular antibiotics commonly known as Amoxil® and Augmentin®, today reopened its Bristol, Tenn. manufacturing facility, which had slipped into bankruptcy and ceased operations last year.
| BRISTOL, Tenn., Aug. 30, 2021 /PRNewswire/ -- USAntibiotics, the sole licensed American maker of penicillin-based Amoxicillin and Amoxil Clavulanate, the popular antibiotics commonly known as Amoxil® and Augmentin®, today reopened its Bristol, Tenn. manufacturing facility, which had slipped into bankruptcy and ceased operations last year. The event marks the first time the facility is under American ownership. When the 360,000-square foot facility comes online, it will have the capacity to produce 300 million capsules and two billion tablets annually and can manufacture and stockpile a five-year supply of Amoxicillin for the United States. Thirty percent of all antibiotics prescribed in the United States each year are Amoxicillin. Upon reopening, USAntibiotics will be the only American company able to manufacture this life saving antibiotic. At full capacity, the facility in Bristol, TN will be able to meet 100 percent of the nation’s demand for Amoxicillin. Every dose of Amoxicillin that will be needed in the United States over the next five years can be manufactured and stored at the USAntibiotics facility, supplying the entire U.S. strategic stockpile. This shift is a complete reversal of the current situation where every dose is sourced from outside the USA. “As the first doses of USAntibiotics’ life-saving drugs move down the assembly line, America will have declared its independence from Chinese antibiotics,” said Rick Jackson, founder, CEO, and chairman of Jackson Healthcare, which purchased the Bristol facility from bankruptcy earlier this year. “Our mission is to solve our nation’s reliance on foreign Amoxicillin and create a secure stockpile that will stand the test of time. Beginning today, the United States is back in the business of essential medicines.” Shane Jackson, president of Jackson Healthcare, said that before acquiring USAntibiotics, the company heard numerous stories of dedicated people who worked without pay to keep the plant operational while in bankruptcy. “When we heard about the selflessness of these individuals, we knew that the company would be a perfect addition to the Jackson Healthcare family of companies,” said Shane Jackson. “Their dedication to making the vital medications Americans need, even in the face of adversity, is inspiring and demonstrates their commitment to solving the supply-chain challenges long term.” Federal and statewide elected officials, including Tennessee Governor Bill Lee and Congresswoman Diana Harshbarger, will participate in a ceremonial ribbon cutting alongside USAntibiotics associates and representatives from Jackson Healthcare later today. In 2008, every U.S.-administered dose of Amoxil and Augmentin was produced in America. After years of declining pharmaceutical production capacity, American healthcare has had to source every capsule of these life-saving drugs from foreign countries, primarily China, resulting in grave U.S. national security and supply chain concerns. Earlier this year, President Joe Biden directed his administration to conduct a review of crucial U.S. supply chains, including pharmaceuticals. Foreign pharmaceutical supply chain consolidation has made essential medicines and raw materials acutely vulnerable to disruptions from mismanagement, natural disasters, pandemics and economic weaponization. The USAntibiotics antibiotics manufacturing facility is among the first wave of private-sector action to strengthen, secure and advance America’s pharmaceutical production capacity. About USAntibiotics About Jackson Healthcare
SOURCE Jackson Healthcare |
View original content:
